< Back to companies

Eaglenos Co., Ltd., established in 2017, brings together top talents in chemistry, materials, electronics, software, machinery, biomedical engineering and other fields. Adhering to the core values of "quality, innovation, cooperation and accountability", Eaglenos is committed to the innovation in electrochemistry, microfluidics, signal acquisition and automation technologies. We have launched a series of accurate POCT products for various diseases such as diabetes, hyperuricemia, cardiovascular and cerebrovascular diseases. Eaglenos started its formal operation in June 2018 and has continuously expanded and developed. With an investment of 150 million RMB, the company has an R&D base of over 9,000 square meters in Jiangbei New Area, including international standard R&D labs, GMP production workshops and automated production lines, etc.

Only accessible to MedStartr community members. Join now

Company Info

Founded
2017
Website
www.eaglenos.com/

Categories

Point-of-Care DevicesDiagnosticsDiabetesCardiovascular Disease
Only accessible to MedStartr community members. Join now

What do you think of Eaglenos (晶捷生物科)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Innovation

Clinical Benefit

Feasibility

Scalability

Only accessible to MedStartr community members. Join now